ASH 2023 | TargetRx to highlight advances of TGRX-678 in CML

2023-11-03 Views:

The 65th Annual Meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from December 9-12, 2023. As one of the world’s largest and most prestigious hematology academic conferences, the ASH Annual Meeting brings together well-known hematology experts from all over the world every year to share the most cutting-edge research progress and breakthrough clinical outcomes.

TGRX-678: Two latest research abstracts were accepted for oral presentation and poster display at the 65th ASH conference.

TGRX-678, a novel BCR-ABL allosteric inhibitor for the treatment of chronic myeloid leukemia (CML), is set to present the results of its Phase I clinical trial and preclinical research for the first time at the 2023 ASH Annual Meeting.


2023 ASH

Oral Presentation

Abstract Title

Safety and Efficacy of TGRX-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Submission ID


Session Name

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches


Qian Jiang,Peking University Peoples Hospital

Presentation Time

Monday, December 11, 2023 3:15 PM


Marriott Marquis San Diego Marina, Pacific


2023 ASH

Poster Presentation

Abstract Title

TGRX-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism  with Ponatinib to Suppress the Highly Resistant Compound Mutations

Submission ID


Session Name

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster Ⅱ

Presentation Time

Sunday, December 10, 2023 6:00 PM - 8:00 PM


San Diego Convention Center, Halls G-H


About TGRX-678

TGRX-678 is a novel BCR-ABL allosteric inhibitor for Chronic Myeloid Leukemia (CML). Unlike the marketed 1st-3rd generation BCR-ABL Tyrosine Kinase Inhibitors (TKIs) that act at the catalytic site, TGRX-678 was developed by specifically targeting the ABL myristol pocket (STAMP), thus locking the kinase into an inactive state and strongly inhibiting its kinase activity. TGRX-678 has the potential to treat refractory and resistant CML patients, including those who failed Ponatinib or Asciminib. TGRX-678 is currently undergoing clinical trials both in China and in US.